328 related articles for article (PubMed ID: 17287460)
1. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity.
Aerts JM; Ottenhoff R; Powlson AS; Grefhorst A; van Eijk M; Dubbelhuis PF; Aten J; Kuipers F; Serlie MJ; Wennekes T; Sethi JK; O'Rahilly S; Overkleeft HS
Diabetes; 2007 May; 56(5):1341-9. PubMed ID: 17287460
[TBL] [Abstract][Full Text] [Related]
2. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
Bijl N; Sokolović M; Vrins C; Langeveld M; Moerland PD; Ottenhoff R; van Roomen CP; Claessen N; Boot RG; Aten J; Groen AK; Aerts JM; van Eijk M
Hepatology; 2009 Nov; 50(5):1431-41. PubMed ID: 19731235
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice.
Bietrix F; Lombardo E; van Roomen CP; Ottenhoff R; Vos M; Rensen PC; Verhoeven AJ; Aerts JM; Groen AK
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):931-7. PubMed ID: 20167657
[TBL] [Abstract][Full Text] [Related]
4. The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells.
Bijl N; Scheij S; Houten S; Boot RG; Groen AK; Aerts JM
J Pharmacol Exp Ther; 2008 Sep; 326(3):849-55. PubMed ID: 18550691
[TBL] [Abstract][Full Text] [Related]
5. Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation.
van Eijk M; Aten J; Bijl N; Ottenhoff R; van Roomen CP; Dubbelhuis PF; Seeman I; Ghauharali-van der Vlugt K; Overkleeft HS; Arbeeny C; Groen AK; Aerts JM
PLoS One; 2009; 4(3):e4723. PubMed ID: 19305508
[TBL] [Abstract][Full Text] [Related]
6. Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
Langeveld M; van den Berg SA; Bijl N; Bijland S; van Roomen CP; Houben-Weerts JH; Ottenhoff R; Houten SM; van Dijk KW; Romijn JA; Groen AK; Aerts JM; Voshol PJ
Metabolism; 2012 Jan; 61(1):99-107. PubMed ID: 21816446
[TBL] [Abstract][Full Text] [Related]
7. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice.
Bijl N; van Roomen CP; Triantis V; Sokolovic M; Ottenhoff R; Scheij S; van Eijk M; Boot RG; Aerts JM; Groen AK
Hepatology; 2009 Feb; 49(2):637-45. PubMed ID: 19072830
[TBL] [Abstract][Full Text] [Related]
8. Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.
Lombardo E; van Roomen CP; van Puijvelde GH; Ottenhoff R; van Eijk M; Aten J; Kuiper J; Overkleeft HS; Groen AK; Verhoeven AJ; Aerts JM; Bietrix F
PLoS One; 2012; 7(10):e38520. PubMed ID: 23056165
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
Shen C; Bullens D; Kasran A; Maerten P; Boon L; Aerts JM; Van Assche G; Geboes K; Rutgeerts P; Ceuppens JL
Int Immunopharmacol; 2004 Jul; 4(7):939-51. PubMed ID: 15182733
[TBL] [Abstract][Full Text] [Related]
10. Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man.
Wennekes T; van den Berg RJ; Donker W; van der Marel GA; Strijland A; Aerts JM; Overkleeft HS
J Org Chem; 2007 Feb; 72(4):1088-97. PubMed ID: 17243712
[TBL] [Abstract][Full Text] [Related]
11. Ceramides and glucosylceramides are independent antagonists of insulin signaling.
Chavez JA; Siddique MM; Wang ST; Ching J; Shayman JA; Summers SA
J Biol Chem; 2014 Jan; 289(2):723-34. PubMed ID: 24214972
[TBL] [Abstract][Full Text] [Related]
12. Glycosphingolipids and insulin resistance.
Aerts JM; Boot RG; van Eijk M; Groener J; Bijl N; Lombardo E; Bietrix FM; Dekker N; Groen AK; Ottenhoff R; van Roomen C; Aten J; Serlie M; Langeveld M; Wennekes T; Overkleeft HS
Adv Exp Med Biol; 2011; 721():99-119. PubMed ID: 21910085
[TBL] [Abstract][Full Text] [Related]
13. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin.
Platt FM; Reinkensmeier G; Dwek RA; Butters TD
J Biol Chem; 1997 Aug; 272(31):19365-72. PubMed ID: 9235935
[TBL] [Abstract][Full Text] [Related]
14. The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1.
Herrera Moro Chao D; Wang Y; Foppen E; Ottenhoff R; van Roomen C; Parlevliet ET; van Eijk M; Verhoek M; Boot R; Marques AR; Scheij S; Mirzaian M; Kooijman S; Jansen K; Wang D; Mergen C; Seeley RJ; Tschöp MH; Overkleeft H; Rensen PCN; Kalsbeek A; Aerts JMFG; Yi CX
Diabetes; 2019 Dec; 68(12):2223-2234. PubMed ID: 31578192
[TBL] [Abstract][Full Text] [Related]
15. Ganglioside GM3 participates in the pathological conditions of insulin resistance.
Tagami S; Inokuchi Ji J; Kabayama K; Yoshimura H; Kitamura F; Uemura S; Ogawa C; Ishii A; Saito M; Ohtsuka Y; Sakaue S; Igarashi Y
J Biol Chem; 2002 Feb; 277(5):3085-92. PubMed ID: 11707432
[TBL] [Abstract][Full Text] [Related]
16. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy.
Fox TE; Han X; Kelly S; Merrill AH; Martin RE; Anderson RE; Gardner TW; Kester M
Diabetes; 2006 Dec; 55(12):3573-80. PubMed ID: 17130506
[TBL] [Abstract][Full Text] [Related]
17. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase.
Yew NS; Zhao H; Hong EG; Wu IH; Przybylska M; Siegel C; Shayman JA; Arbeeny CM; Kim JK; Jiang C; Cheng SH
PLoS One; 2010 Jun; 5(6):e11239. PubMed ID: 20574539
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of acetic acid-induced gastric ulcer formation in rats by glucosylceramide synthase inhibitors.
Nakashita M; Suzuki H; Miura S; Taki T; Uehara K; Mizushima T; Nagata H; Hibi T
Dig Dis Sci; 2013 Feb; 58(2):354-62. PubMed ID: 22918683
[TBL] [Abstract][Full Text] [Related]
19. Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
Wennekes T; Meijer AJ; Groen AK; Boot RG; Groener JE; van Eijk M; Ottenhoff R; Bijl N; Ghauharali K; Song H; O'Shea TJ; Liu H; Yew N; Copeland D; van den Berg RJ; van der Marel GA; Overkleeft HS; Aerts JM
J Med Chem; 2010 Jan; 53(2):689-98. PubMed ID: 20000679
[TBL] [Abstract][Full Text] [Related]
20. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.
Nietupski JB; Pacheco JJ; Chuang WL; Maratea K; Li L; Foley J; Ashe KM; Cooper CG; Aerts JM; Copeland DP; Scheule RK; Cheng SH; Marshall J
Mol Genet Metab; 2012 Apr; 105(4):621-8. PubMed ID: 22366055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
